Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q4 2020

Q4 2020 biggest moves
  • HZNPHZNP

    HORIZON THERAPEUTICS PUB L

    Sold out

    was 3.5% of portfolio

  • BIIBBIIB

    Biogen

    New

    2.2% of portfolio

  • CYTKCYTK

    Cytokinetics

    New

    1.0% of portfolio

  • CNCCNC

    Centene

    Added 33%

    now 2.9% of portfolio

114 changes in all

Top Holdings129 positions

Checking export access…
Activity:
VTRS

Viatris Inc.

15.7M$294.7M5.8%$14.970.00%
1 qtr
New
95
??
INVITAE CORPDelisted
Bond
163.4M$263.8M5.2%——
2 qtrssince 2020-Q3
Unchanged
0
??
NEVRO CORPDelisted
Bond
115.8M$208.5M4.1%——
5 qtrssince 2019-Q4
Unchanged
0
??
NUVASIVE INCDelisted
Bond
200M$201.3M4.0%——
4 qtrssince 2020-Q1
Increased
90
GRAY
GRAYDelisted

GRAYBUG VISION INC

5.3M$153.3M3.0%——
2 qtrssince 2020-Q3
Unchanged
0
CNC

Centene Corporation

2.4M$145.9M2.9%$60.25-0.36%
5 qtrssince 2019-Q4
Increased
66
149.6M$137.1M2.7%——
2 qtrssince 2020-Q3
Unchanged
0
AFIB
AFIBDelisted

ACUTUS MED INC

4.3M$125.1M2.5%——
2 qtrssince 2020-Q3
Unchanged
0
LRMR

Larimar Therapeutics, Inc.

5.1M$110.1M2.2%$12.85+66.61%
3 qtrssince 2020-Q2
Unchanged
0
BIIB

Biogen Inc.

448,000$109.7M2.2%$244.860.00%
1 qtr
New
78
SWTX
SWTXAcquired

SPRINGWORKS THERAPEUTICS INC

1.4M$104.6M2.1%——
5 qtrssince 2019-Q4
Increased
60
54.8M$92.5M1.8%——
2 qtrssince 2020-Q3
Decreased
0
ONCR
ONCRDelisted

ONCORUS INC

2.8M$92.1M1.8%——
1 qtr
New
68
ALXN
ALXNDelisted

ALEXION PHARMACEUTICALS INC

579,248$90.5M1.8%——
3 qtrssince 2020-Q2
Unchanged
0
NKTX

Nkarta, Inc.

1.4M$87.3M1.7%$30.06+104.49%
2 qtrssince 2020-Q3
Decreased
0
RYTM

Rhythm Pharmaceuticals, Inc.

2.7M$80.9M1.6%$25.01+18.87%
5 qtrssince 2019-Q4
Increased
63
??
INSULET CORPDelisted
Bond
57.6M$76.4M1.5%——
1 qtr
New
68
??
INSMED INCDelisted
Bond
61M$69.2M1.4%——
4 qtrssince 2020-Q1
Unchanged
0
AHCO

AdaptHealth Corp.

1.8M$67.8M1.3%$14.31+162.40%
5 qtrssince 2019-Q4
Increased
49
PCRX

Pacira BioSciences, Inc.

1M$62.8M1.2%$33.93+76.34%
4 qtrssince 2020-Q1
Decreased
0
$5.1B
AUM
129
Positions
Q4 2020
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2020-Q1$3,151,113,0000.539146165786%
2020-Q2$3,433,887,0008.97378164477%
2020-Q3$4,106,901,00019.5991889075%
2020-Q4$5,059,782,00023.2019471616%
Activity profile
$ moved · Q4'20
New45%Increased14%Decreased9%Exited32%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.2 quarters
<1Q33%1-4Q19%1-2Y31%2Y+17%

Deerfield Management Company, L.P. manages $5.1B across 129 positions as of Q4 2020. Top holdings: VTRS (5.8%), INVITAE CORP (5.2%), NEVRO CORP (4.1%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$5B
VTRS5.82%
INVITAE CORP5.21%
NEVRO CORP4.12%
NUVASIVE INC3.98%
GRAY3.03%
CNC2.88%
AERIE PHARMA2.71%
AFIB2.47%
LRMR2.18%
BIIB2.17%
Other2.07%

Portfolio allocation by GICS sector

Sectors2
Healthcare63.44%
Unknown36.56%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used